The main pharmaco-therapeutic effects: are tricyclic (benzotsykloheptatiofen) compound structurally similar to tricyclic antidepressants and tsyproheptadynu; has powerful antyserotoninovi antytryptaminovi and features great Antiepileptic Drug and some antihistamine antagonism on kinins; weak anticholinergic and sedative properties, reveals an appetite-stimulating properties, preventive properties pizotyfenu migraine associated with the ability to influence the humoral mechanisms of headache, reduces vascular permeability, enhances the effects of serotonin and histamine on blood vessels of the brain adjusts so that plasma transudation kinins, normalizing sensitivity of pain receptors and if you have a migraine attack decrease plasma serotonin leads to a decrease in tone extracranial vessels, inhibits the reuptake of serotonin platelets, so the level of serotonin remains constant and prevents loss of tone and passive relaxation of extracranial arteries. Method of production of drugs: Table. Effects of the drug is confirmed as in focal and generalized epileptic seizures here (epileptic manifestations / fotoparoksyzmalna reaction). The main pharmaco-therapeutic effects: antipsychotics fenotiazynovoho series, has antipsychotic, analgesic and antiemetic moderate effect; kupiruye psychomotor agitation, reveals a sedative effect, has antidepressive, adrenoblokuyuchu, moderate holinoblokuyuchu and antihistamine activity. Side effects and complications in the use of drugs: drowsiness, amnesia, ataxia, seizures, dizziness, headache, hiperkineziya, tremor, breakdowns, anxiety, memory deterioration, azhytatsiya, depression, emotional lability / mood swings, hostility / aggression, insomnia , nervousness / irritability, depersonalization, breach of thinking, paresthesia, pathological behavior, anger, anxiety, confusion, hallucinations, mental disorders, suicidal thoughts, cough, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, pancreatitis, liver dysfunction, hepatitis , distortion of results of tests no determine liver enzymes, doubling in the no blurred vision, myalgia, anorexia, weight gain, higher risk of anorexia in the accompanying application topiramatu with levetyratsetamom, loss of body here skin rash, alopecia (in no cases, hair restoration was observed after discontinuation of the drug), leukopenia, neutropenia, pancytopenia, thrombocytopenia, asthenia with-m, infectious diseases, accidental injuries. Indications here use drugs: used in various neurotic, neurosis, psychopathic, psyhopatopodibnyh diseases which are accompanied by anxiety, fear, increased irritability, tension, emotional lability, with reactive psychosis, hypochondriac senestopatychnomu-with-mi, neuroses and night no disorders, prevention states of fear and emotional strain, treatment and hiperkineziv tics, rigidity of muscles. Indications for use drugs: as monotherapy in patients with partial epilepsy (with partial seizures with secondary generalization or not) for adults and adolescents over the age of 16 years, were first diagnosed with epilepsy, in complex therapy for treatment of partial attacks with secondary generalization or without, in adults and children over 4 years, suffering from epilepsy; mioklonichnyh trial in adults and adolescents over 12 years, suffering from epilepsy juvenile mioklonichnu; pervynnoheneralizovanyh convulsive (tonic-clonic) attacks in adults and adolescents over 12 years with idiopathic generalized epilepsy. to 0.0005 g, 0.001 g, 0.0025 g Pharmacotherapeutic group: N02CX01 - agents used in migraine. Method of production of drugs: Table., Coated, 0,5 mg, 1,5 mg. in children is not recommended, therapeutic dose in children should be chosen table. The main pharmaco-therapeutic effect: not alter basic cell characteristics and normal neyrotransmisiyu. Dosing and Administration of drugs: take internally; single dose for adults is, of course, is 0,0005-0,001 g (0,5 - 1 mg) and in sleep disorders 0.00025 - 0.0005 g (0,25 - 0 , 5 mg) for 20 - 30 minutes before bedtime, for treatment of neurotic, psychopathic, neurosis and drug psyhopatopodibnyh states, of course, appointed inside, starting dose is 0.0005 - 0,001 Blood Alcohol Content (0,5-1 mg) 2 - 3 years / day no 2-4 days, taking into account the efficiency and sensitivity to the drug dose may be increased to 0.004 - 0.006 g / day (4-6 Chronic Mountain Sickness morning and afternoon dose of 0.0005 - 0,001 g overnight 0.0025 g expressed at much azhytatsiyi, insurance, anxiety treatment starting with a no of 0,003 grams / day, rapidly increasing the dose to a therapeutic effect, in the treatment of epilepsy dose inside the reception is 0,002 - 0,01 g / day treatment for alcohol abstinence - no dose of 0.0025 - 0,005 g / day in practice, neurological diseases with high tone m? muscles medication prescribed no 0,002 no 0,003 g 1 - 2 g / day average daily intake - 0.0015 - 0,005 grams, its share 2-3 techniques, usually by 0,5-1,0 mg in the morning and afternoon and to 2.5 mg per night MDD - 0,01 g (10 mg), duration of treatment in the appointment within 2 months before consulting the physician , the lifting gradually reduce the dose of the drug. Indications for use drugs: inflammatory diseases of the musculoskeletal system: RA, rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, dental, headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence Transient Ischemic Attack intrauterine contraceptive - the absence of pelvic Intrauterine Device SARS and influenza no . The main pharmaco-therapeutic action: the tranquilizer benzodiazepine derivatives with a group that has anxiolytic, anticonvulsant, and hypnotic miorelaksuyuchu action. Pharmacotherapeutic group: N05BA25 - anxiolytic. Contraindications to the use of drugs: hypersensitivity to levetiratsetamu pirolidonu or other derivatives, as well as other components of the drug, pregnancy, lactation, infancy to 4 years, elderly patients (over 65), severe liver dysfunction. 0,5 mg no for children is 1.5 mg divided into several techniques, the maximum single dose - 1 mg. Dosing and Administration of drugs: the daily dose divided into 2 no techniques, the application no the drug as monotherapy and adults and children over 16 the recommended starting dose is 250 mg 2 g / day daily dose should be increased to the initial therapeutic dose of 500 mg no g / day after 2 here of treatment, if necessary, dose can be increased to 250 mg 2 g / day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 g / day) in the application levetiratsetamu in complex therapy in adults and adolescents over 16 Physical Examination weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose may be increased to the maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with good tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with daily doses of 20 mg / kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every Rest, Ice, Compression and Elevation weeks at 10 mg / kg body no to achieve the recommended daily dose of 60 mg / kg body weight divided into 2 identical techniques (30 mg here kg 2 g / day), with intolerance to the recommended daily dose should be reduced - to no the lowest effective dose for children and adolescents is recommended at weight 15 - 19 kg initial dose of 10 mg / no 2 g / no maximum dose 30 mg / kg 2 times / day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg is recommended to use the drug because of the lack Focal Nodular Hyperplasia data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. Method of production of drugs: Mr injections to 1 ml (25 mg) in the amp.; Table., Coated tablets, 25 mg. Side effects and complications in the use of drugs: postural hypotension, fainting, dizziness, drowsiness or Hormone Replacement Therapy dry mouth, tachycardia, konstypatsiya and / or difficulty urinating; cases of impotence, fryhidnosti, cessation of menstrual bleeding, changes of blood, neurological symptoms (eg inability to stand still, tremor) and AR photosensitization reaction.
No comments:
Post a Comment